Biosimilar behemoth Alvotech has entered into an exclusive commercialization agreement with Polifarma for AVT06, a proposed biosimilar to Regeneron’s Eylea (aflibercept), in the Turkish market. Alvotech will be responsible for the manufacturing and development of the drug, while Polifarma will handle market registration and commercialization.
Alvotech Links Up With Polifarma On Proposed Eylea Biosimilar
AVT06 Is Currently Undergoing Clinical Development
Alvotech has signed an agreement with Polifarma to distribute its proposed aflibercept biosimilar in Turkey. The compound, AVT06, is currently in the development stage.
